title: [Clinicopathological and survival features of primary hepatic lymphoma: an analysis of 35 cases].
abstract: OBJECTIVE
  To evaluate the clinicopathological features and prognosis of primary hepatic lymphoma (PHL).
  
  
  METHODS
  Thirty-five patients with PHL who underwent surgical resection and were confirmed by pathology in our hospital from 1982 to 2012 were re-evaluated for clinicopathological data, including their symptoms, radiological features, recurrence interval, histopathological properties and prognosis.
  
  
  RESULTS
  Of the 35 patients, 25 were men (71.4%) and 10 were women (28.6%), with an average age of 52.6 years old (range, 17-79 years). Presented symptoms were epigastric phymatosis, abdominal pain and low-grade fever. In the present study, 21 (60.0%) patients were positive for HBsAg, 1(2.9%) patient was positive for anti-HCV, 3 patients were positive for AFP, 12 patients and 2 patients were complicated by cirrhosis and hepatocellular carcinoma, respectively. Pathologically, 35 PHL were classified into 19 DLBCL (54.3%), 13 T cell-lymphoma (37.1%), and 3 MALT lymphoma (8.6%). Patients with DCBCL showed better postoperative survival than patients with T cell-lymphoma (31.7 ± 3.2) months vs. (22.9 ± 2.2) months (P < 0.05).
  
  
  CONCLUSIONS
  Hepatitis B virus (HBV) infection may contribute to the pathogenesis of Chinese patients with PHL. Surgical resection followed by comprehensive therapy is the first-line option for PHL. The prognosis of patients with PHL is associated with PHL subtypes.
authors: Department of Pathology, Easten Hepatobilliary Surgery Hospital, the Second Millitary Medical University, Shanghai 200438, China.
authors: Qian
authors: Q
authors: Zhao
authors: Department of Pathology, Easten Hepatobilliary Surgery Hospital, the Second Millitary Medical University, Shanghai 200438, China.
authors: Hai-ping
authors: HP
authors: Liu
authors: Department of Pathology, Easten Hepatobilliary Surgery Hospital, the Second Millitary Medical University, Shanghai 200438, China.
authors: Yi-jin
authors: YJ
authors: Gu
authors: Department of Pathology, Easten Hepatobilliary Surgery Hospital, the Second Millitary Medical University, Shanghai 200438, China. Email: wmcong@smmu.edu.cn.
authors: Wen-ming
authors: WM
authors: Cong
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018951:Antigens, CD20 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy / Q000821:virology; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications*; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D018937:Hepatitis C Antibodies / Q000378:metabolism; D006801:Humans; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy / Q000821:virology; D008223:Lymphoma / Q000473:pathology / Q000628:therapy / Q000821:virology; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000628:therapy / Q000821:virology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology / Q000628:therapy / Q000821:virology; D016399:Lymphoma, T-Cell / Q000473:pathology / Q000628:therapy / Q000821:virology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D018951:Antigens, CD20; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D000509:alpha-Fetoproteins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D017493:Leukocyte Common Antigens; D011241:Prednisone